Verona Pharma PLC at Jefferies Healthcare Conference Transcript
We are lucky to have the Verona team joining me today. To the left of me, Dave Zaccardelli, CEO, and I believe President, if I'm recalling correctly. And then to the left of him is Chris Martin, SVP of Commercial. Welcome both of you.
Thank you.
Thank you.
So for those in the audience who might not be as familiar with the Verona story, could you possibly spend two to three minutes just briefly talking about your company? What your lead asset is, what its value proposition is? And then maybe talk about what kind of news flow we can expect over the next 6 to 12 months.
Yeah, happy. Thanks, Andrew. Yeah. So Verona Pharma has the asset, ensifentrine, which is a novel PDE3, PDE4 inhibitor, and as such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
